Vinorelbine Plus Fluorouracil in Treating Women With Metastatic Breast Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00003730|
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : July 2, 2012
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Randomized clinical trial to study the effectiveness of vinorelbine plus fluorouracil in treating women who have metastatic breast cancer that has been previously treated with at least one regimen of chemotherapy.
|Condition or disease||Intervention/treatment|
|Breast Cancer||Drug: fluorouracil Drug: vinorelbine tartrate|
- Determine the least toxic time of vinorelbine administration when combined with chronomodulated fluorouracil in women with previously treated metastatic breast cancer.
- Determine the toxic effects and dose intensities of each drug in these women.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to prior chemotherapy (second line vs third line) and participating center. Patients are randomized to 1 of 8 vinorelbine dosing times (0000, 0300, 0600, 0900, 1200, 1500, 1800, or 2100).
Patients receive vinorelbine IV over 20 minutes on days 1 and 6 and fluorouracil IV over 12 hours according to a chronomodulated delivery rate (2200 to 1000 with a maximum dose at 0400) on days 1-4. Treatment repeats every 3 weeks for at least 3 courses in the absence of unacceptable toxicity.
Patients are followed for 30 days.
PROJECTED ACCRUAL: A minimum of 80 patients (10 per dosing time) will be accrued for this study.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||80 participants|
|Official Title:||A Multicenter Randomized Trial, With Direct Individual Benefit, to Determine the Optimal Circadian Time of Vinorelbine Administration Combined With Chronomodulated Infusion of 5-Fluorouracil in Previously Treated Patients With Metastatic Breast Cancer|
|Study Start Date :||December 1998|
|Primary Completion Date :||November 2004|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00003730
|VZW Monica Campus Eeuwfeestkliniek|
|Antwerpen, Belgium, 2010|
|C.H.C - Asbl|
|Liege, Belgium, B 4000|
|CHU Liege - Domaine Universitaire du Sart Tilman|
|Liege, Belgium, B-4000|
|Centre Jean Perrin|
|Clermont-Ferrand, France, 63011|
|Centre de Lutte Contre le Cancer Georges-Francois Leclerc|
|Dijon, France, 21079|
|Hopital Perpetuel Secours|
|Levallois-Perret, France, 92300|
|Centre Hospital Regional Universitaire de Limoges|
|Limoges, France, 87042|
|Paris, France, 75475|
|Centre Rene Huguenin|
|Saint Cloud, France, 92211|
|Saint Etienne, France, 42055|
|Hopital Paul Brousse|
|Villejuif, France, 94804|
|University Hospital of Heraklion|
|Iraklion (Heraklion), Crete, Greece, 71110|
|Istituto per la Ricerca e Cura del Cancro|
|Candiolo (Turin), Italy, 10180|
|Ospedale San Carlo Borromeo|
|Milano (Milan), Italy, 20153|
|Azienda Ospedale S. Luigi - Universita Di Turin|
|Orbassano, (Torino), Italy, 10043|
|Fondazione Salvatore Maugeri|
|Pavia, Italy, I-27100|
|Istituti Fisioterapici Ospitalieri - Roma|
|Rome, Italy, 00161|
|Study Chair:||Bruno Coudert, MD||Centre Georges Francois Leclerc|